288 related articles for article (PubMed ID: 19706150)
1. Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii.
Pothoulakis C
Aliment Pharmacol Ther; 2009 Oct; 30(8):826-33. PubMed ID: 19706150
[TBL] [Abstract][Full Text] [Related]
2. [Recent advances in Saccharomyces boulardii research].
Im E; Pothoulakis C
Gastroenterol Clin Biol; 2010 Sep; 34 Suppl 1():S62-70. PubMed ID: 20889007
[TBL] [Abstract][Full Text] [Related]
3. Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes.
Dalmasso G; Cottrez F; Imbert V; Lagadec P; Peyron JF; Rampal P; Czerucka D; Groux H; Foussat A; Brun V
Gastroenterology; 2006 Dec; 131(6):1812-25. PubMed ID: 17087945
[TBL] [Abstract][Full Text] [Related]
4. Review article: yeast as probiotics -- Saccharomyces boulardii.
Czerucka D; Piche T; Rampal P
Aliment Pharmacol Ther; 2007 Sep; 26(6):767-78. PubMed ID: 17767461
[TBL] [Abstract][Full Text] [Related]
5. [Saccharomyces boulardii activates expression of peroxisome proliferator-activated receptor-gamma in HT-29 cells].
Lee SK; Kim HJ; Chi SG; Jang JY; Nam KD; Kim NH; Joo KR; Dong SH; Kim BH; Chang YW; Lee JI; Chang R
Korean J Gastroenterol; 2005 May; 45(5):328-34. PubMed ID: 15908765
[TBL] [Abstract][Full Text] [Related]
6. Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis.
Chen X; Kokkotou EG; Mustafa N; Bhaskar KR; Sougioultzis S; O'Brien M; Pothoulakis C; Kelly CP
J Biol Chem; 2006 Aug; 281(34):24449-54. PubMed ID: 16816386
[TBL] [Abstract][Full Text] [Related]
7. Saccharomyces boulardii CNCM I-745: A Non-bacterial Microorganism Used as Probiotic Agent in Supporting Treatment of Selected Diseases.
Kaźmierczak-Siedlecka K; Ruszkowski J; Fic M; Folwarski M; Makarewicz W
Curr Microbiol; 2020 Sep; 77(9):1987-1996. PubMed ID: 32472262
[TBL] [Abstract][Full Text] [Related]
8. Review of Saccharomyces boulardii as a treatment option in IBD.
Sivananthan K; Petersen AM
Immunopharmacol Immunotoxicol; 2018 Dec; 40(6):465-475. PubMed ID: 29771163
[TBL] [Abstract][Full Text] [Related]
9. Systematic review with meta-analysis: Saccharomyces boulardii for treating acute gastroenteritis in children-a 2020 update.
Szajewska H; Kołodziej M; Zalewski BM
Aliment Pharmacol Ther; 2020 Apr; 51(7):678-688. PubMed ID: 32056266
[TBL] [Abstract][Full Text] [Related]
10. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa.
Castagliuolo I; Riegler MF; Valenick L; LaMont JT; Pothoulakis C
Infect Immun; 1999 Jan; 67(1):302-7. PubMed ID: 9864230
[TBL] [Abstract][Full Text] [Related]
11. Saccharomyces boulardii in childhood.
Vandenplas Y; Brunser O; Szajewska H
Eur J Pediatr; 2009 Mar; 168(3):253-65. PubMed ID: 19096876
[TBL] [Abstract][Full Text] [Related]
12. Diversity of
Czerucka D; Rampal P
World J Gastroenterol; 2019 May; 25(18):2188-2203. PubMed ID: 31143070
[TBL] [Abstract][Full Text] [Related]
13. Intestinal anti-inflammatory effect of the probiotic Saccharomyces boulardii in DSS-induced colitis in mice: Impact on microRNAs expression and gut microbiota composition.
Rodríguez-Nogales A; Algieri F; Garrido-Mesa J; Vezza T; Utrilla MP; Chueca N; García F; Rodríguez-Cabezas ME; Gálvez J
J Nutr Biochem; 2018 Nov; 61():129-139. PubMed ID: 30236870
[TBL] [Abstract][Full Text] [Related]
14. Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum.
Castagliuolo I; LaMont JT; Nikulasson ST; Pothoulakis C
Infect Immun; 1996 Dec; 64(12):5225-32. PubMed ID: 8945570
[TBL] [Abstract][Full Text] [Related]
15. A new therapeutic association to manage relapsing experimental colitis: Doxycycline plus Saccharomyces boulardii.
Garrido-Mesa J; Algieri F; Rodriguez-Nogales A; Utrilla MP; Rodriguez-Cabezas ME; Zarzuelo A; Ocete MA; Garrido-Mesa N; Galvez J
Pharmacol Res; 2015 Jul; 97():48-63. PubMed ID: 25917208
[TBL] [Abstract][Full Text] [Related]
16. Saccharomyces boulardii ameliorates clarithromycin- and methotrexate-induced intestinal and hepatic injury in rats.
Duman DG; Kumral ZN; Ercan F; Deniz M; Can G; Cağlayan Yeğen B
Br J Nutr; 2013 Aug; 110(3):493-9. PubMed ID: 23279717
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children.
Szajewska H; Skórka A; Dylag M
Aliment Pharmacol Ther; 2007 Feb; 25(3):257-64. PubMed ID: 17269987
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of Saccharomyces boulardii in liver diseases: from passive bystander to protective performer?
Cui B; Lin L; Wang B; Liu W; Sun C
Pharmacol Res; 2022 Jan; 175():106022. PubMed ID: 34883213
[TBL] [Abstract][Full Text] [Related]
19. Saccharomyces boulardii ameliorates Citrobacter rodentium-induced colitis through actions on bacterial virulence factors.
Wu X; Vallance BA; Boyer L; Bergstrom KS; Walker J; Madsen K; O'Kusky JR; Buchan AM; Jacobson K
Am J Physiol Gastrointest Liver Physiol; 2008 Jan; 294(1):G295-306. PubMed ID: 18032474
[TBL] [Abstract][Full Text] [Related]
20. [Saccharomyces boulardii CNCM I-745 influences the gut-associated immune system].
Stier H; Bischoff SC
MMW Fortschr Med; 2017 Jun; 159(Suppl 5):1-6. PubMed ID: 28643294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
